Newron :: Press Releases

Newron awarded European patent for use of ralfinamide in migraine 20/12/2007	ENG	GER
Newron initiates development of NW-3509 03/12/2007	ENG	GER
Newron and Merck Serono report initiation of the MOTION study, a new phase III clinical trial of safinamide in Parkinson’s disease 28/11/2007	ENG	GER
Newron starts clinical phase II development of ralfinamide in post-surgical pain 02/10/2007	ENG	GER
Newron reports half-year results 2007 03/09/2007	ENG	GER
Newron builds a presence in Switzerland with the opening of a clinical development facility in Basle 30/08/2007	ENG	GER
Newron Announces 18-Month Safety and Efficacy Data of Phase III Trial of Safinamide in PD 22/08/2007	ENG	GER
Newron Reports Additional Analyses of Ralfinamide Phase II Study 17/07/2007	ENG	GER
Newron Phase III data of safinamide in Parkinsons' disease available later in July 17/07/2007	ENG	GER
Newron reports positive Phase II results for ralfinamide in neuropathic pain 02/07/2007	ENG	GER
Newron announces FDA approval of US IND application for ralfinamide in neuropathic pain 29/06/2007	ENG	GER
Newron gains option to full global rights for use of ralfinamide in pain 29/06/2007	ENG	GER
Promising Data on cognitive effects of safinamide in early Parkinson’s disease 08/06/2007	ENG	GER
Newron Announces Presentation of Data on Cognitive Effects in Early Parkinson’s Disease at Movement Disorder Society’s 11th International Congress 01/06/2007	ENG	GER
Professor Ruggero Fariello retiring from Newron’s Board 29/05/2007	ENG	GER
Newron appoints Carlos de Sousa as new Chief Business Officer 03/05/2007	ENG	GER
Newron Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson’s Disease at the American Academy of Neurology 59th Annual Meeting - down-loadable presentation under investors section 27/04/2007	ENG	GER
Newron Pharmaceuticals reports 2006 financial results 27/03/2007	ENG	GER
Newron completes recruitment for ralfinamide Phase II MTD study in neuropathic pain 08/03/2007	ENG	GER
Newron Pharmaceuticals awarded favorable interference judgements by US patent and trademark office 15/01/2007	ENG	GER

Discovering and developing innovative therapeutics for CNS disorders

Media

Press Releases - 2007

Newron awarded European patent for use of ralfinamide in migraine

Newron initiates development of NW-3509

Newron and Merck Serono report initiation of the MOTION study, a new phase III clinical trial of safinamide in Parkinson’s disease

Newron starts clinical phase II development of ralfinamide in post-surgical pain

Newron reports half-year results 2007

Newron builds a presence in Switzerland with the opening of a clinical development facility in Basle

Newron Announces 18-Month Safety and Efficacy Data of Phase III Trial of Safinamide in PD

Newron Reports Additional Analyses of Ralfinamide Phase II Study

Newron Phase III data of safinamide in Parkinsons' disease available later in July

Newron reports positive Phase II results for ralfinamide in neuropathic pain

Newron announces FDA approval of US IND application for ralfinamide in neuropathic pain

Newron gains option to full global rights for use of ralfinamide in pain

Promising Data on cognitive effects of safinamide in early Parkinson’s disease

Newron Announces Presentation of Data on Cognitive Effects in Early Parkinson’s Disease at Movement Disorder Society’s 11th International Congress

Professor Ruggero Fariello retiring from Newron’s Board

Newron appoints Carlos de Sousa as new Chief Business Officer

Newron Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson’s Disease at the American Academy of Neurology 59th Annual Meeting - down-loadable presentation under investors section

Newron Pharmaceuticals reports 2006 financial results

Newron completes recruitment for ralfinamide Phase II MTD study in neuropathic pain

Newron Pharmaceuticals awarded favorable interference judgements by US patent and trademark office